In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:

• Current therapies
  • Studies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDF
  • Kaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis B
  • Early vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV Transmission
• Investigational functional cure strategies
  • B-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV Infection
  • MARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV Infection
  • REEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHB
  • HBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV Infection
  • CVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV Infection

Presenter:
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Link to full program: 
https://bit.ly/47XJlU4